EST. 2027 · GENOMICS · MACHINE LEARNING

Biology is now readable. The consequences are not.

FibiOS reads the living code: machine learning, genomics, and the Systems Technology quietly rewriting medicine. Evidence first, hype last.

Browse the ledger

The Architecture

The Core Pillars

FibiOS operates at the intersection of biology, law, and infrastructure. We decode the science, the regulation, and the technology driving modern medicine.

"The artifact is not the behavior."

Output is not outcome. An AI can generate a perfect-looking file, but that doesn't mean it reflects reality.

"The check is not the proof."

Passing an automated test doesn't guarantee truth. We don't rely on scripts; we read the primary literature.

"The record is not the truth until someone has gone and looked."

The ultimate human anchor. Every figure we publish is traced, verified, and signed off by an editor.

PILLAR 01 / 03

AI Biotech

The Science

Deep learning for CRISPR, protein structure, and computational chemistry.

We track the shift from finding molecules in a lab to methodically designing them on a screen.

PILLAR 02 / 03

UK Regulation

The Rules

Navigating the UK’s regulatory machinery: MHRA approvals, NICE cost-effectiveness, and the geopolitics of health data.

We track the sandboxes, the systemic bottlenecks, and the legal battles dictating how the state balances medical innovation with patient safety.

PILLAR 03 / 03

Infrastructure

The Systems

Genomics England, the NHS Federated Data Platform, and national AI supercomputing. Infrastructure is the invisible therapy.

We track the data pipelines and compute clusters that form the digital scaffolding of the clinic—and the engineering limits that dictate what the science can actually do.

Biology was never silent. It was unread.

For a century we carried its language in fragments — a protein at a time, a pathway at a time, a patient at a time. The instruments were patient. The hands were careful. The ledger filled slowly.

Then the machines learned to read.

Why we exist

FibiOS exists for what comes after that threshold. We are a publication about the moment biology stopped being a body of facts and became a body of text that can be parsed, predicted, and in places rewritten.

We are not here to sell you the future. We are here to read it alongside you — carefully, and in order.

The ledger

Evidence first, hype last.

  • How AI is Accelerating CRISPR Gene Editing

    Machine learning has moved guide RNA design from trial and error toward prediction, and generative models are now proposing editors not found in nature.

    Juno Uni Hera

  • The Future of Personalized Medicine in 2027

    Sequencing is now cheap and interpretation is not. Where precision medicine actually stands in 2027, and what the next twelve months must settle.

    Juno Uni Hera

  • Reading the Genome at Population Scale

    Large cohorts have made human genetic variation readable at scale. The open question is whether that signal changes decisions in a clinic.

    Juno Uni Hera

  • Models That Propose Molecules

    Generative models now suggest drug candidates faster than laboratories can test them. The constraint has moved from finding ideas to clearing assays.

    Juno Uni Hera

  • Protein Structure After AlphaFold

    Structure prediction did not end experimental biology. It changed which structures are worth solving in a laboratory first.

    Juno Uni Hera

  • The MHRA and AI: Regulating the Black Box

    Britain's device regulator accepts that AI products change after approval. The lifecycle rules that would make that enforceable are still drafts.

    Juno Uni Hera

  • NICE and the Price of a Cure

    A one-time gene therapy meets a threshold built for yearly costs. NICE approved the treatment only inside a managed access agreement.

    Juno Uni Hera

  • Genomics England and the Data Commons

    A national sequencing programme built a research library from patient genomes. The Generation Study is now testing the model on newborn screening.

    Juno Uni Hera

  • Post-Brexit Clinical Trials: The New Framework

    New UK clinical trials regulations took effect in April 2026 after a delayed start. The approval timetable they serve is a government target.

    Juno Uni Hera

  • The UK's Pro-Innovation AI Framework

    Britain regulates artificial intelligence sector by sector, through existing bodies and non-statutory principles. The promised legislation has not arrived.

    Juno Uni Hera

  • What the Federated Data Platform Actually Federates

    Federation here means separate hospital-level instances that choose what to share, not one national database holding every record.

    Juno Uni Hera

  • Secure Data Environments and the Access Turn

    The NHS is replacing copies of patient data with controlled access inside twelve secure environments, and a new company will run the front door.

    Juno Uni Hera

  • How the NHS Buys Cloud

    NHS cloud dependence is visible in DNS records and invisible in contract values, which is why the same service looks concentrated and competitive at once.

    Juno Uni Hera

  • What the UK's AI Compute Is For

    The UK is expanding public AI compute twentyfold by 2030, and the harder problem is deciding who gets the GPU hours rather than buying the machines.

    Juno Uni Hera

  • The Clinical Genomics Pipeline

    England's genomic testing service is measured against turnaround targets rather than published averages, and the gap between the two is the whole story.

    Juno Uni Hera